Titan Pharmaceuticals, Inc. (TTNP)
| Market Cap | 32.45M |
| Revenue (ttm) | 5.00M |
| Net Income (ttm) | -19.10M |
| Shares Out | 3.26M |
| EPS (ttm) | -7.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $3.31 |
| Previous Close | $3.34 |
| Change ($) | -0.03 |
| Change (%) | -0.90% |
| Day's Open | 3.34 |
| Day's Range | 3.10 - 3.42 |
| Day's Volume | 1,166,861 |
| 52-Week Range | 2.82 - 16.35 |
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated h...
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredite...
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-fo...
The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has increased by 34.75% from $0.13 per share to $0.17 per share. This is an explanation of why it happened.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended Se...
Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a pr...
Titan Pharmaceuticals (TTNP) is making news on Wednesday after announcing a deal with JT Pharma to acquire one of its assets. The post Titan Pharmaceuticals News: 8 Things for TTNP Stock Inves...
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases...
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders a...
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2020 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 8, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today urged its stockholders to vote "FOR" an amendment to its c...
SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Inde...
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2020 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended Mar...
In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q3 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q2 2019 Results - Earnings Call Transcript
On Wednesday, August 14, Titan Pharmaceuticals (NASDAQ: TTNP) will release its latest earnings report.
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q1 2019 Results - Earnings Call Transcript
Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2018 Results - Earnings Call Transcript
About TTNP
Titan Pharmaceuticals, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based i... [Read more...]
| Industry Biotechnology | IPO Date Jan 18, 1996 |
| Stock Exchange NASDAQ | Ticker Symbol TTNP |
Financial Performance
In 2019, TTNP's revenue was $3.61 million, a decrease of -45.44% compared to the previous year's $6.62 million. Losses were -$16.46 million, 82.4% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for TTNP stock is "Buy" and the 12-month stock price forecast is 11.00.